JP2022164858A5 - - Google Patents

Download PDF

Info

Publication number
JP2022164858A5
JP2022164858A5 JP2022139098A JP2022139098A JP2022164858A5 JP 2022164858 A5 JP2022164858 A5 JP 2022164858A5 JP 2022139098 A JP2022139098 A JP 2022139098A JP 2022139098 A JP2022139098 A JP 2022139098A JP 2022164858 A5 JP2022164858 A5 JP 2022164858A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022139098A
Other versions
JP2022164858A (ja
Filing date
Publication date
Priority claimed from JP2018554677A external-priority patent/JP7198670B2/ja
Application filed filed Critical
Publication of JP2022164858A publication Critical patent/JP2022164858A/ja
Publication of JP2022164858A5 publication Critical patent/JP2022164858A5/ja
Pending legal-status Critical Current

Links

JP2022139098A 2016-04-20 2022-09-01 免疫調整性il2r融合タンパク質およびその使用 Pending JP2022164858A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662325428P 2016-04-20 2016-04-20
US62/325,428 2016-04-20
JP2018554677A JP7198670B2 (ja) 2016-04-20 2017-04-20 免疫調整性il2r融合タンパク質およびその使用
PCT/US2017/028693 WO2017184901A1 (en) 2016-04-20 2017-04-20 Immunomodulatory il2r fusion proteins and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018554677A Division JP7198670B2 (ja) 2016-04-20 2017-04-20 免疫調整性il2r融合タンパク質およびその使用

Publications (2)

Publication Number Publication Date
JP2022164858A JP2022164858A (ja) 2022-10-27
JP2022164858A5 true JP2022164858A5 (ja) 2023-06-27

Family

ID=58710057

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018554677A Active JP7198670B2 (ja) 2016-04-20 2017-04-20 免疫調整性il2r融合タンパク質およびその使用
JP2022139098A Pending JP2022164858A (ja) 2016-04-20 2022-09-01 免疫調整性il2r融合タンパク質およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018554677A Active JP7198670B2 (ja) 2016-04-20 2017-04-20 免疫調整性il2r融合タンパク質およびその使用

Country Status (6)

Country Link
US (1) US20190127435A1 (ja)
EP (1) EP3445847A1 (ja)
JP (2) JP7198670B2 (ja)
CN (1) CN109312304A (ja)
CA (1) CA3021455A1 (ja)
WO (1) WO2017184901A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY196588A (en) * 2015-03-05 2023-04-19 Hutchinson Fred Cancer Res Immunomodulatory Fusion Proteins and uses Thereof
AU2018236461A1 (en) 2017-03-17 2019-09-19 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
CN109503715B (zh) * 2017-09-15 2023-12-15 科济生物医药(上海)有限公司 Il-4r的融合蛋白及其应用
CN108504685A (zh) * 2018-03-27 2018-09-07 宜明细胞生物科技有限公司 一种利用CRISPR/Cas9系统同源重组修复IL-2RG缺陷基因的方法
CN110615843B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含第三信号受体的嵌合抗原受体及其应用
CN110582515A (zh) * 2018-11-12 2019-12-17 天境生物科技(上海)有限公司 包含cd47抗体和细胞因子的融合蛋白
KR20220028090A (ko) * 2019-06-28 2022-03-08 카파 테라퓨틱스 리미티드 이식 반응에 저항하는 세포 및 방법
US20210238258A1 (en) * 2019-09-11 2021-08-05 The Board Of Trustees Of The Leland Stanford Junior University Chimeric orthogonal receptor proteins and methods of use
WO2021055372A1 (en) * 2019-09-16 2021-03-25 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
US20230030680A1 (en) * 2020-01-07 2023-02-02 St. Jude Children's Research Hospital, Inc Chimeric gmcsf-il18 receptor
CN113249330A (zh) * 2021-05-20 2021-08-13 深圳市先康达生命科学有限公司 免疫细胞及其应用
WO2023081727A1 (en) * 2021-11-02 2023-05-11 Fred Hutchinson Cancer Center Treatments for cancers utilizing cell-targeted therapies and associated research protocols

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5747292A (en) * 1993-04-06 1998-05-05 Fred Hutchinson Cancer Research Center Chimeric cytokine receptors in lymphocytes
WO2002056910A1 (en) * 2001-01-17 2002-07-25 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
WO2013063419A2 (en) * 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
AU2013221672B2 (en) 2012-02-13 2017-11-09 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof

Similar Documents

Publication Publication Date Title
JP2022164858A5 (ja)
BR102023012440A2 (ja)
BR102023010976A2 (ja)
BR102023009641A2 (ja)
BR102023008688A2 (ja)
BR102023007252A2 (ja)
BR102023005164A2 (ja)
BR102023001987A2 (ja)
BR102023001877A2 (ja)
BR102023000289A2 (ja)
BR102022026909A2 (ja)
BR102022023461A2 (ja)
BR202022009269U2 (ja)
BR202022005961U2 (ja)
BR202022001779U2 (ja)
BR202022000931U2 (ja)
BY13143U (ja)
BY13152U (ja)
BY13137U (ja)
BY13138U (ja)
BY13139U (ja)
BY13140U (ja)
BY13141U (ja)
BY13142U (ja)
BY13135U (ja)